Blocking Antibodies

Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)

Also Known As:

Networked: 1116 relevant articles (72 outcomes, 98 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Postow, Michael A: 10 articles (01/2021 - 01/2014)
2.	Konishi, Eiji: 8 articles (09/2017 - 12/2011)
3.	Wolchok, Jedd D: 7 articles (01/2021 - 01/2011)
4.	Yamanaka, Atsushi: 7 articles (09/2017 - 11/2012)
5.	Callahan, Margaret K: 6 articles (01/2021 - 01/2014)
6.	Harris, Eva: 5 articles (10/2021 - 02/2013)
7.	Alitalo, Kari: 5 articles (01/2021 - 09/2010)
8.	Diamond, Michael S: 5 articles (01/2018 - 02/2013)
9.	Thurston, Gavin: 4 articles (01/2021 - 12/2010)
10.	Ferrara, Napoleone: 4 articles (01/2020 - 01/2006)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2021 - "The exhausted MAIT cells have reduced polyfunctionality with regard to production of important anti-tumor effector molecules, and blocking antibodies to PD-1 partly improved activation of tumor-infiltrating MAIT cells in vitro. " 01/01/2021 - "Identification of the B7-H3 receptor will improve our understanding of its role in tumor immunity, and will suggest rational strategies to develop blocking antibodies, which may enhance the therapeutic efficacy of tumor immunity." 11/01/2020 - "PD-L1/PD-1 blocking antibodies have demonstrated therapeutic efficacy across a range of human cancers. " 02/01/2016 - "Blocking antibodies against immunosuppressive molecules have shown promising results in cancer patients. " 01/01/2022 - "Compelling experimental data and clinical reports about PD-1/PD-L1-blocking antibodies in patients with PDS suggest its use as first line treatment in unresectable or metastatic tumor stages. "
2.	Melanoma (Melanoma, Malignant) 01/01/2017 - "Antibodies blocking programmed cell death 1 (PD-1) have encouraging responses in patients with metastatic melanoma. " 03/01/2016 - "Herein, we review the current clinical data supporting the use of checkpoint-blocking antibodies in the treatment of melanoma and highlight outstanding clinical questions and unmet clinical needs. " 11/01/2015 - "Immune checkpoint-blocking antibodies targeting CTLA-4 and PD-1 result in significant activity and prolonged survival in patients with advanced melanoma and are currently available for clinical use. " 02/01/2015 - "PD-L1 expression in melanoma correlates with response to PD-1 pathway-blocking antibodies. " 05/01/2012 - "However, continuous investigation on the immune mediated rejection of melanoma cells has led to the development of effective antibodies blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4), a critical negative regulator of the antitumor T-cell response. "
3.	Infections 01/01/2017 - "PD-1 signaling inhibits STAT5 phosphorylation and the removal of this brake by knocking down PD-1 expression or by using anti-PD-1 blocking antibodies, translated in vivo into better clearance of helminth worm infection in mice." 12/01/2021 - "The data constitute unprecedented direct experimental evidence that suboptimal efficacy of infection-blocking antibodies, while not completely preventing primary infection, has a pronounced benefit in reducing the number of relapses. " 01/01/2020 - "Loss-of-function studies using soluble receptors, blocking antibodies, RNA interference, and gene knockout demonstrated that hDSG2 predominantly mediated HAdV55 infection. " 04/01/2012 - "Whether enhancing antibodies raised against VP4 can play a role in iterative homologous and/or heterologous CV-B infections and in the persistence of viruses within the host deserves further study." 09/20/2023 - "Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2."
4.	Inflammation (Inflammations) 01/01/2020 - "These data show that VitD3 increases efficacy of both SCIT and SLIT, by enhancing induction of blocking antibodies and suppression of airway inflammation, underscoring the relevance of proficient VitD3 levels for successful AIT." 01/01/2022 - "We therefore hypothesize that neutrophil count and neutrophil-to-lymphocyte ratio could serve as markers of therapeutic efficiency for IL-17A-blocking antibodies in the context of active inflammation." 01/01/2019 - "In this model, IL-38 knockout (IL-38 KO) mice show delayed disease resolution with exacerbated IL-17-mediated inflammation, which is reversed by the administration of mature IL-38 or γδ T cell-receptor-blocking antibodies. " 01/01/2018 - "Inhibition of the interaction between h-IAPP and RAGE by sRAGE, RAGE-blocking antibodies, or genetic RAGE deletion protected pancreatic islets, β cells, and smooth muscle cells from h-IAPP-induced inflammation and metabolic dysfunction. " 10/01/2016 - "Treatment with blocking antibodies to CD1a alleviated skin inflammation. "
5.	Malaria 02/01/2003 - "These results suggest that the selection of sufficiently diverse antibody panels, from which mosquitocidal or malaria transmission-blocking antibodies can be isolated, may require improved selection methods or specifically enriched pre-immunized libraries." 01/01/2018 - "To our knowledge, this is the first report of the generation of a CV using Pfs25 and malaria specific GPI where the GPI is shown to enhance the ability of Pfs25 to elicit transmission blocking antibodies." 09/16/2010 - "Antibodies blocking cytoadhesion are important mediators of malaria immunity acquired by endemic populations. " 01/01/1989 - "falciparum and known to be a sensitive target of malaria transmission-blocking antibodies. " 11/08/2021 - "While clinical trials have reported that Pfs25-based vaccines are safe and effective in inducing transmission-blocking antibodies, the extent of the genetic diversity of Pfs25 in malaria endemic populations has rarely been studied. "

Related Drugs and Biologics

1.	Ligands
2.	Programmed Cell Death 1 Receptor
3.	Immune Checkpoint Inhibitors
4.	B7-H1 Antigen
5.	Antibodies
6.	Vaccines
7.	Mitogen-Activated Protein Kinases
8.	Interleukin-17 (Interleukin 17)
9.	Complement System Proteins (Complement)
10.	Chemokines

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)
5.	Microbubbles